Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 218K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zorn, E. Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Zorn, E. Articles by Ritz, J. Social Bookmarking                      What's this?

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115
² Department of Medicine, Brigham and Women's Hospital, Boston MA 02115
³ Harvard Medical School, Boston, MA 02115

Address correspondence to Jerome Ritz, Dana-Farber Cancer Institute, 44 Binney Street, M530, Boston, MA 02115. Phone: (617) 632-3465; Fax: (617) 632-5167; email: Jerome_ritz{at}dfci.harvard.edu

We examined the immune response to DBY, a model H-Y minor histocompatibility antigen (mHA) in a male patient with chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplant from a human histocompatibility leukocyte antigen (HLA)-identical female sibling. Patient peripheral blood mononuclear cells were screened for reactivity against a panel of 93 peptides representing the entire amino acid sequence of DBY. This epitope screen revealed a high frequency CD4⁺ T cell response to a single DBY peptide that persisted from 8 to 21 mo after transplant. A CD4⁺ T cell clone displaying the same reactivity was established from posttransplant patient cells and used to characterize the T cell epitope as a 19-mer peptide starting at position 30 in the DBY sequence and restricted by HLA-DRB1*1501. Remarkably, the corresponding X homologue peptide was also recognized by donor T cells. Moreover, the T cell clone responded equally to mature HLA-DRB1*1501 male and female dendritic cells, indicating that both DBY and DBX peptides were endogenously processed. After transplant, the patient also developed antibodies that were specific for recombinant DBY protein and did not react with DBX. This antibody response was mapped to two DBY peptides beginning at positions 118 and 536. Corresponding DBX peptides were not recognized. These studies provide the first demonstration of a coordinated B and T cell immune response to an H-Y antigen after allogeneic transplant. The specificity for recipient male cells was mediated by the B cell response and not by donor T cells. This dual DBX/DBY antigen is the first mHA to be identified in the context of chronic GVHD.

Key Words: minor histocompatibility antigen • chronic graft-versus-host disease • hematopoietic stem cell transplantation • H-Y antigen • class II epitope

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kapur, R., Ebeling, S., Hagenbeek, A. (2008). B-cell involvement in chronic graft-versus-host disease. haematol 93: 1702-1711 [Abstract] [Full Text]  
• Friedrichs, B., Siegel, S., Kloess, M., Barsoum, A., Coggin, J. Jr., Rohrer, J., Jakob, I., Tiemann, M., Heidorn, K., Schulte, C., Kabelitz, D., Steinmann, J., Schmitz, N., Zeis, M. (2008). Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia. J. Immunol. 180: 6374-6384 [Abstract] [Full Text]  
• Rosinski, K. V., Fujii, N., Mito, J. K., Koo, K. K. W., Xuereb, S. M., Sala-Torra, O., Gibbs, J. S., Radich, J. P., Akatsuka, Y., Van den Eynde, B. J., Riddell, S. R., Warren, E. H. (2008). DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111: 4817-4826 [Abstract] [Full Text]  
• Sarantopoulos, S., Stevenson, K. E., Kim, H. T., Bhuiya, N. S., Cutler, C. S., Soiffer, R. J., Antin, J. H., Ritz, J. (2007). High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. Clin. Cancer Res. 13: 6107-6114 [Abstract] [Full Text]  
• Chen, J., Ellison, F. M., Eckhaus, M. A., Smith, A. L., Keyvanfar, K., Calado, R. T., Young, N. S. (2007). Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells. J. Immunol. 178: 4159-4168 [Abstract] [Full Text]  
• Mullally, A., Ritz, J. (2007). Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 109: 1355-1362 [Abstract] [Full Text]  
• Almeciga, I., Wang, Z. C., Zuniga, J., Fernandez-Vina, M., Clavijo, O., Araujo, H., Romero, V., Henry, J., Ferrone, S., Yunis, E. J. (2006). Allorecognition of an HLA-A*01 Aberrant Allele by an HLA Identical Family Member Carrying the HLA-A*0101 Allele. J. Immunol. 177: 8643-8649 [Abstract] [Full Text]  
• Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., Macdonell, R., Pasek, M., Lee, S. J., Ho, V., Soiffer, R., Antin, J. H., Ritz, J., Alyea, E. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108: 756-762 [Abstract] [Full Text]  
• Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L., Zorn, E., Lee, S. J., Hochberg, E. P., Wu, C. J., Alyea, E. P., Cutler, C., Ho, V., Soiffer, R. J., Antin, J. H., Ritz, J. (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105: 2973-2978 [Abstract] [Full Text]  
• Torikai, H., Akatsuka, Y., Miyazaki, M., Warren, E. H. III, Oba, T., Tsujimura, K., Motoyoshi, K., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T. (2004). A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene. J. Immunol. 173: 7046-7054 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS